Skip to main content
. Author manuscript; available in PMC: 2009 Sep 24.
Published in final edited form as: Atherosclerosis. 2008 Sep 27;204(2):483–490. doi: 10.1016/j.atherosclerosis.2008.09.021

Fig. 3.

Fig. 3

Simvastatin significantly decreased plasma adiponectin levels (mean % changes; 10%, P = 0.012 by paired t-test) and insulin sensitivity (mean % changes; 6%, P = 0.007 by paired t-test) when compared with baseline. Pravastatin significantly increased plasma adiponectin levels (mean % changes; 9%, P = 0.011 by paired t-test) and insulin sensitivity (mean % changes; 6%, P = 0.008 by paired t-test) when compared with baseline. Moreover, these effects of pravastatin were significant when compared with placebo and simvastatin (P < 0.001 for adiponectin and P = 0.001 for QUICKI by ANOVA). Pl, placebo; S20, simvastatin 20 mg; P40, pravastatin 40 mg. Standard error of the mean is identified by the bars.